Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;121(9):725-737.
doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Alessandro Leonetti  1   2 , Sugandhi Sharma  2 , Roberta Minari  1 , Paola Perego  3 , Elisa Giovannetti  4   5 , Marcello Tiseo  1   6
Affiliations
Review

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

Alessandro Leonetti et al. Br J Cancer. 2019 Oct.

Abstract

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene addiction. Despite the documented efficacy of osimertinib in first- and second-line settings, patients inevitably develop resistance, with no further clear-cut therapeutic options to date other than chemotherapy and locally ablative therapy for selected individuals. On account of the high degree of tumour heterogeneity and adaptive cellular signalling pathways in NSCLC, the acquired osimertinib resistance is highly heterogeneous, encompassing EGFR-dependent as well as EGFR-independent mechanisms. Furthermore, data from repeat plasma genotyping analyses have highlighted differences in the frequency and preponderance of resistance mechanisms when osimertinib is administered in a front-line versus second-line setting, underlying the discrepancies in selection pressure and clonal evolution. This review summarises the molecular mechanisms of resistance to osimertinib in patients with advanced EGFR-mutated NSCLC, including MET/HER2 amplification, activation of the RAS-mitogen-activated protein kinase (MAPK) or RAS-phosphatidylinositol 3-kinase (PI3K) pathways, novel fusion events and histological/phenotypic transformation, as well as discussing the current evidence regarding potential new approaches to counteract osimertinib resistance.

PubMed Disclaimer

Conflict of interest statement

M.T.: advisory boards and speakers’ fee for Astra-Zeneca. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Resistance mechanisms reported for osimertinib according to the line of treatment. The two pie charts depict resistance mechanisms that have been identified in tissue and/or in plasma after resistance to second-line and first-line osimertinib, respectively. Only studies that enrolled more than 15 patients have been taken into account for the ranges of the percentages. In some cases, different molecular aberrations might co-exist in the same patient
Fig. 2
Fig. 2
Schematic representation of the known mechanisms of resistance to osimertinib Resistance mechanisms to osimertinib can consist of EGFR modifications (mutation/amplification), bypass pathway activation, downstream pathway activation, epithelial-to-mesenchymal transition (EMT), histologic transformation, oncogenic gene fusions and cell-cycle gene aberrations. Abbreviations: act, activation; amp, amplification; del, deletion; mut, mutation
Fig. 3
Fig. 3
Potential treatment algorithm of T790M EGFR-mutated NSCLC. The present figure depicts the most common molecular events within EGFR that can occur after the onset of osimertinib resistance. (1) T790M loss/C797S: in this scenario, NSCLC cells re-acquire sensitivity to first-generation and second-generation EGFR-TKIs; (2) T790M/C797S in cis: NSCLC cells are amenable to novel fourth-generation EGFR-TKIs which are currently in development and (3) T790M/C797S in trans: NSCLC cells become sensitive to combination therapy with osimertinib and first-generation EGFR-TKIs
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009;361:958–967. - PubMed
    1. Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) J. Thorac. Oncol. 2014;9:154–162. - PMC - PubMed
    1. Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat. Rev. Clin. Oncol. 2018;15:694–708. - PubMed
    1. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat. Rev. 2018;65:1–10. - PubMed
    1. Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Disco. 2014;4:1046–1061. - PMC - PubMed

Publication types

MeSH terms